Archive
 
Video Library
Broadcast
 
Broadcast ScheduleChannel LocatorAffiliatesDaily Streaming Schedule
About
 
About the Ohio ChannelFrequently Asked QuestionsContact UsJob OpportunitiesSite RequirementsMedia Information
 
 
A SERVICE OF OHIO'S PUBLIC BROADCASTING STATIONS
A SERVICE OF OHIO'S PUBLIC BROADCASTING STATIONS
ARCHIVEBROADCASTABOUT
Total Views 87,659,461
Total Views 87,659,461
Broadcast Schedule Channel Locator Affiliates Daily Streaming Schedule
 
 
About The Ohio Channel Frequently Asked Questions Contact Us Job Opportunities Site Requirements Media Information
 
 
 
The Sound of Ideas - 6-21-2023 - A Cleveland Clinic doctor discusses impact of new weight loss drugs Expand
 
 
June 21, 2023
06-21-2023
39 Views
Share Download
 
Start At    sec      End At    sec
 
Link
Embed Code
Available Versions
Download 720p Video
 
 
To download a video: right-click on the version you'd like to save, then choose "Save Link As..." and save to your desktop.
 
Collections
The Sound of Ideas
 
Description
Obesity is a global health problem. The World Health Organization says that worldwide obesity has tripled since 1975. Here in the United States, the National Institute of Diabetes and Digestive and Kidney Diseases says 42% of adults are considered obese. This means they have a BMI of 30 or greater.

The National Institutes of Health describes obesity as a gateway disease because it increases the risk someone will develop other conditions including heart disease, diabetes and cancer.

Americans spend billions each year on weight loss and weight loss related services and products. Now a new class of drugs is making headlines for their weight loss benefits. They are known as GLP-1 or glucagon-like peptide agonists. You know them better by their brand names that are heavily advertised: Ozempic, Rybelsus and Trulicity to name a few.

Ozempic is the best-known of the drugs or semaglutide as it's called generically. Scientists developed it as a Type 2 diabetes drug that resulted in weight loss for many patients. Its manufacturer, Novo Nordisk, then developed Wegovy-which is specially approved for weight loss. Both of those drugs are delivered by injection. A third formulation, Rybelsus is a pill form.

We are going to talk about the new GLP-1 drugs and whether they represent-- as some headlines have suggested-- a game-change, for the treatment of obesity to start Wednesday's "Sound of Ideas."

Later in the hour, we bring you're the latest episode of our new podcast, "Living for We." The podcast explores the livability issues raised by a 2020 Bloomberg City Lab article on a study that found Cleveland ranked dead last for Black women. This week, we turn our attention to education. We hear about how Black women often navigate systems that encouraged them to aim low and think small and are steered away from honors courses or otherwise are limited by the narrow expectations of others.

Guests:

-Reena Bose, MD, Obesity Medicine, Endocrine and Metabolic Institute, Cleveland Clinic
-Marlene Harris-Taylor, Director of Engaged Journalism, IPM, Podcast Executive Producer & Host
-Leah Hudnall, Cleveland State University
-Tait Manning, Enlightened Solutions
-Chinenye Nkemere, Enlightened Solutions
-Shemariah Arki, Ed.D., Kent State University
-Angela Neal-Barnett, Ph.D., Kent State University
 
 
 
Copyright Disclaimer Terms of Use Contact Us Support
 
 
© 2025 The Ohio Channel / ideastream.
All Rights Reserved.